First Pass

20 stories from 7 sources

Outbreak urgency meets a push to remake drug markets

Day’s Recap

Supporting Articles

12:24 PMAl Jazeera

Over 6,000 Ebola cases confirmed in DRC as death toll nears 3,000

Summary

More than 6,000 Ebola cases have been confirmed in the Democratic Republic of the Congo, with deaths approaching 3,000. The outbreak is spreading rapidly as the country struggles to contain infections.

The scale and speed of transmission point to a response crisis, not merely a rising

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

A rapidly expanding Ebola outbreak threatens to overwhelm local health systems and increase regional transmission risk.

Link to Story
4:20 PMCNBC

Trump strikes new drug pricing deals with nine midsized drugmakers

Summary

Trump is expected to announce agreements with nearly a dozen drugmakers as his administration pushes to tie U.S. drug prices to lower prices abroad. The deals would extend the administration's effort to reduce medication costs.

The agreements would shift the administration's drug-pricing campaign from broad demands toward company-specific commitments. Their

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

The announcements could give Trump a concrete affordability win while testing whether negotiated deals can change U.S. prices at scale.

Link to Story

2 stories · 2 sources

1:07 PMBloomberg Markets

Lilly to Buy Merida for $2.88 Billion in Autoimmune Push

Summary

Eli Lilly plans to acquire Merida Biosciences for up to $2.88 billion in cash, adding autoimmune and allergy treatments to a portfolio dominated by diabetes and weight-loss drugs. The deal is part of more than $20 billion in acquisitions Lilly has announced in 2026, focused largely on earlier-stage medicines.

Lilly is using Zepbound and Mounjaro cash flows to reduce its dependence on a narrow

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

The acquisition shows how obesity-drug profits are reshaping pharmaceutical dealmaking and funding a broader race for the next blockbuster.

Link to Story

2 stories · 2 sources

3:00 PMPYMNTS

Cigna Is Using AI to Intervene Earlier in Care

Summary

Cigna is expanding AI tools that identify members who may need support before conditions worsen, including cancer, heart disease, and kidney disease. The insurer says the expansion will reach 20% more customers and could reduce medical costs by about $200 million over three years.

Cigna is using AI to move intervention upstream, making risk detection and care management a

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

If the program works, insurers could use predictive models to shift spending from late-stage treatment toward earlier, lower-cost care.

Link to Story
4:30 AMStat News

STAT+: After a rough stretch, mRNA gets a boost — at least for now

Summary

Clinical success with a personalized mRNA vaccine for melanoma has renewed confidence in the technology after a difficult period. Researchers hope the result can support more durable progress in other medical applications.

The melanoma result gives mRNA a concrete clinical win, but it does not erase the

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

One strong result could restore investment and credibility, but mRNA's recovery still depends on reproducible results across diseases.

Link to Story

Other Developments

A curated list of other prominent stories from this day.

4:00 PMStat News

New guidelines on migraine prevention reflect increasing options for patients

Summary

New migraine-prevention guidelines address a growing range of available treatments. Their release reflects how preventive care has expanded beyond the older set of therapeutic options.

The expanding treatment menu makes prevention more flexible but also puts greater weight on matching

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

More migraine treatments can improve control, but only if patients and clinicians can navigate the added complexity.

Link to Story
11:56 AMStat News

STAT+: Can buying a drug patent application be seen as a bid to prolong a monopoly?

Summary

A patent dispute involving Amgen is testing whether acquiring a pending drug patent application can amount to an effort to extend market exclusivity. The case could shape how regulators and courts evaluate pharmaceutical patent transactions more broadly.

The central issue is whether a patent purchase represents legitimate control of intellectual property or

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

The case could affect both generic entry timelines and the value of patent deals across the pharmaceutical industry.

Link to Story
11:27 AMStat News

STAT+: GLP-1 drugs are almost single-handedly forcing employers to reconsider workers’ health care

Summary

The article examines how widespread demand for GLP-1 medicines is forcing employers to reassess health benefits and coverage decisions. The broader discussion also touches on litigation involving CVS Health and the potential effects of Medicaid cuts.

GLP-1 coverage is turning a pharmacy benefit into a major workforce cost and retention decision,

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

GLP-1 drugs are shifting healthcare cost decisions from insurers and doctors into corporate compensation strategy.

Link to Story
10:01 AMAl Jazeera

Sleeping in on weekends is good for the heart: What research has shown

Summary

A study found that people who catch up on sleep during weekends had a lower risk of hypertension. The finding adds to evidence linking sleep duration and regularity with cardiovascular health.

The important signal is that weekend recovery sleep may partly offset the effects of insufficient

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

Sleep timing and duration may be modifiable factors in reducing hypertension risk.

Link to Story
9:52 AMScienceDaily

One injection could keep osteoarthritis drugs working for weeks

Summary

Scientists developed an injectable gel that stays in arthritic joints for weeks, gradually releasing medication while improving lubrication. The platform is designed to deliver disease-modifying treatments locally rather than exposing the whole body.

The key shift is sustained, targeted drug delivery from a single injection instead of repeated

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

A longer-lasting joint treatment could make osteoarthritis care more practical and potentially more effective.

Link to Story
9:43 AMScienceDaily

Your waist size may reveal health risks BMI misses

Summary

Researchers found that waist measurement can identify unhealthy body-fat levels nearly as effectively as more complex assessments. BMI alone missed many people who met the researchers' criteria for obesity.

The decisive finding is that BMI can understate risk when it ignores where body fat

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

A simple measurement could improve obesity screening and expose health risks that BMI overlooks.

Link to Story
9:03 AMStat News

STAT+: We’re reading about drug pricing deals, a new cancer therapy approval, and more

Summary

The newsletter roundup covers recent pharmaceutical developments, including drug-pricing agreements and approval of a new cancer therapy. It also surveys additional headlines shaping the drug industry.

The main signal is the continued overlap between access policy and clinical innovation: pricing agreements

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

Drug policy and drug development are moving together, making both price and clinical value central to patient access.

Link to Story
8:48 AMStat News

STAT+: Can a pregnancy hormone steer a cardiovascular treatment?

Summary

The roundup considers whether a pregnancy-related hormone could guide cardiovascular treatment and also covers caution around radiopharmaceuticals and skepticism about mRNA technologies. It presents these as part of a broader set of biotechnology developments.

The defining issue is whether a biological signal associated with pregnancy can be translated into

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

The research could open a new therapeutic path, but biological plausibility alone will not establish cardiovascular benefit.

Link to Story
8:25 AMStat News

A winner, a loser, and a mid-stage signal from a major cardiology research conference

Summary

The report assesses notable results from a major cardiology meeting, including one apparent success, one setback, and an encouraging mid-stage finding. It also covers developments in mental health care and radiopharmaceutical research.

The conference's value lies in separating promising signals from evidence that is ready to change

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

Early cardiology results can reshape research priorities well before they alter treatment guidelines.

Link to Story
6:43 AMScienceDaily

Scientists find why the liver may not heal even after you stop drinking

Summary

Researchers found that alcohol-related liver disease can leave damaged liver cells stuck in a regenerative state, even after alcohol cessation. They linked this failure to inflammation-driven RNA errors and identified a pathway that could potentially be targeted to restore liver repair.

The decisive finding is that stopping alcohol may remove the ongoing injury without fully restoring

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

The work points toward therapies that could improve recovery after abstinence rather than relying on alcohol cessation alone.

Link to Story
6:42 AMEconomic Times

Aurobindo Pharma gains over 3% as subsidiary launches generic Advair Diskus in US; stock up 41% YTD

Summary

Aurobindo Pharma shares rose more than 3% after its subsidiary Lannett launched a generic version of Advair Diskus in the United States in two strengths. The product is the first commercialized medicine from Aurobindo's inhalation pipeline, while the stock had gained 41.16% year to date in 2026.

The launch converts Aurobindo's inhalation strategy into commercial revenue and gives it exposure to a

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

Aurobindo now has a commercial foothold in inhaled medicines, adding a new potential growth channel beyond its established generic portfolio.

Link to Story
4:30 AMStat News

Opinion: The most shocking thing about the latest statistics on CTE in football is that we find them so shocking

Summary

The latest study quantifies the prevalence of chronic traumatic encephalopathy in football players but does not expose a new problem, argues historian Emily Harrison. The findings reinforce longstanding evidence linking repeated head impacts to brain injury.

The shift is evidentiary, not substantive: researchers can now measure a risk that football has

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

Better statistics should narrow the debate from whether the danger exists to how football will reduce it.

Link to Story
4:30 AMStat News

STAT+: Cadre of radiopharmaceuticals experts pushes the bounds in cancer therapy

Summary

Researchers see substantial potential in radiopharmaceuticals, which deliver radiation to cancer cells, but argue that current treatment strategies may be too cautious. A group of specialists is exploring how to use the approach more aggressively.

The central shift is from proving that radiopharmaceuticals work to testing how far their therapeutic

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

The field's next gains may depend less on discovering the therapy than on safely expanding its intensity and range.

Link to Story

Make it yours

Build Your First Pass.

Pick your topics, set your cadence, and receive your personalized First Pass in your inbox. It’s that simple!